How Jean-Marc Vall ée Was Remembered by Friends, Colleagues One Year After His Passing
Auteur Jean-Marc Vallée died on Christmas Day 2021, and, given the sudden nature of his death — the coroner attributed it to “a fatal cardiac arrhythmia secondary to severe coronary atherosclerosis” — and a COVID-19 surge, his Hollywood family wasn’t able to gather to honor his life until a recent…#sharp #santamonica #hbo #biglittlelies #émile #auteurjeanmarcvallée #dallasbuyersclub #thr #nathanross #beach (Source: Reuters: Health)
Source: Reuters: Health - January 6, 2023 Category: Consumer Health News Source Type: news
Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Apple secures patent win in AliveCor heart monitoring tech case
The Patent Trial and Appeal Board determined three AliveCor patents regarding the detection of heart conditions, like cardiac arrhythmias, were unpatentable. (Source: mobihealthnews)
Source: mobihealthnews - December 7, 2022 Category: Information Technology Source Type: news
Life-threatening cardiac arrhythmia and sudden death during electronic gaming: an international case series and systematic review - Lawley CM, Tester M, Sanatani S, Prendiville T, Beach CM, Vinocur JM, Horie M, Uhm JS, Khongphatthanayothin A, Ayers MD, Starling L, Yoshida Y, Shah MJ, Skinner JR, Turner C.
Background
Electronic gaming has recently been reported as a precipitant of life-threatening cardiac arrhythmia in susceptible individuals.
Objective
The purpose of this study was to describe the population at risk, the nature of cardiac events, and ... (Source: SafetyLit)
Source: SafetyLit - November 30, 2022 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Vaping Might Trigger Irregular Heartbeat, Animal Studies Show
FRIDAY, Oct. 28, 2022 -- In another strike against electronic cigarettes, a new mouse study has found that they can cause an irregular heartbeat, also called a cardiac arrhythmia.
Researchers from the University of Louisville ' s Christina Lee Brown... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 28, 2022 Category: General Medicine Source Type: news
Music mogul Jamal Edwards died from a cardiac arrhythmia due to toxic substances
Brenda Edwards - who presents on Loose Women - lost her son earlier this year when he died from a cardiac arrhythmia. (Source: Daily Express - Health)
Source: Daily Express - Health - October 17, 2022 Category: Consumer Health News Source Type: news
Electronic Gaming Can Trigger Cardiac Arrhythmias in Some Children
MONDAY, Oct. 17, 2022 -- In susceptible children, electronic gaming can precipitate lethal cardiac arrhythmias, according to research published online Oct. 10 in Heart Rhythm.
Claire M. Lawley, M.B.B.S., Ph.D., from Sydney Children ' s Hospitals... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 17, 2022 Category: Pharmaceuticals Source Type: news
Biosense Webster Launches the OCTARAY ™ Mapping Catheter with TRUEref™ Technology
IRVINE, CA – September 6, 2022 – Biosense Webster, Inc., part of Johnson & Johnson MedTech[†], today announced the release of the OCTARAY™ Mapping Catheter with TRUEref™ Technology powered by the CARTO™ 3 Version 7 System. The OCTARAY™ Mapping Catheter was developed for the mapping of cardiac arrhythmias, including atrial fibrillation (AFib). The catheter has eight splines with improved electrode spacing options to provide shorter and more efficient mapping times than PENTARAYTM NAV ECO Mapping Catheter, which may shorten overall ablation procedure times.[2],[8],[‡] AFib is the most common type of cardi...
Source: Johnson and Johnson - September 6, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
What is Ondine ’ s Curse?
Discussion
Congenital central hypoventilation syndrome (CCHS) is an autosomal dominant with variable inheritance genetic disease caused by mutation in the Paired Like Homeobox B2 (PHOX2B) gene on chromosome 4. There are two other genes which may also cause CCHS. CCHS affects the chemoreceptor afferent ventilation pathways and is a neural crest migration problem of the autonomic nervous system. The incidence is unknown but a prevalence of 1 in 200,000 live births has been reported. Obviously it is a rarer phenomenon because of the general lethality of the syndrome.
Patients usually present at birth or soon afterwards, but o...
Source: PediatricEducation.org - August 15, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Cardiogenic shock due to yew poisoning rescued by VA-ECMO: case report and literature review - Schreiber N, Manninger M, P ätzold S, Reisinger AC, Hatzl S, Hackl G, Högenauer C, Eller P.
Ingestion of leaves of the European yew tree (Taxus baccata) can result in fatal cardiac arrhythmias and acute cardiogenic shock. This cardiotoxicity derives from taxine alkaloids that block cardiac voltage-gated sodium and calcium channels. Prompt initiat... (Source: SafetyLit)
Source: SafetyLit - August 11, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
The Significance of Widely Split P Waves The Significance of Widely Split P Waves
This case highlights the need to be aware that the presence of widely split P waves on an ECG may proceed to more serious cardiac arrhythmias during an anesthetic procedure.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2022 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
New IMBRUVICA ® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Updated data from the FD cohort with three years of follow-up shows that I+V continues to demonstrate deep and durable responses and clinically meaningful progression-free survival (PFS) and overall survival (OS) in the first-line tre...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
